Diagnosis and management of chronic graft‐versus‐host disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  British Journal of Haematology

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2012.09128.xPMID 22533811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Organ‐specific management and supportive care in chronic graft‐versus‐host disease

  2012cited by this paper
• Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD

  2012cited by this paper
• Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.

  2012cited by this paper
• Diagnosis and management of acute graft‐versus‐host disease

  2012cited by this paper
• Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

  2011cited by this paper
• Diagnosis and staging of chronic graft-versus-host disease in the clinical practice.

  2011cited by this paper
• Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis.

  2011cited by this paper
• Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

  2011cited by this paper
• Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin

  2011cited by this paper
• Current management of GISTs.

  2010influential reference
• Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

  2010cited by this paper
• Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

  2010cited by this paper
• A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease

  2010cited by this paper
• Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.

  2010cited by this paper
• Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

  2010cited by this paper
• Alefacept treatment for refractory chronic extensive GVHD

  2009cited by this paper
• Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

  2009cited by this paper
• Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

  2009cited by this paper
• Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease

  2009cited by this paper
• Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP).

  2009cited by this paper
• Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

  2009cited by this paper
• First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.

  2009cited by this paper
• Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

  2009influential reference
• Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti‐thymocyte globulin

  2009cited by this paper
• Extracorporeal photopheresis: what is it and when should it be used?

  2009cited by this paper
• Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.

  2009cited by this paper
• How can we help patients with refractory chronic graft versus host disease- single centre experience.

  2009cited by this paper
• U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease

  2009cited by this paper
• Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.

  2009cited by this paper
• Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.

  2009cited by this paper
• Recognizing and managing chronic graft-versus-host disease.

  2008cited by this paper
• High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem Cell Transplantation.

  2008cited by this paper
• Rituximab as salvage therapy for refractory chronic GVHD

  2008cited by this paper
• A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.

  2008cited by this paper
• Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.

  2008cited by this paper
• U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T‐cell lymphoma and chronic graft‐versus‐host disease

  2008cited by this paper
• Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.

  2008cited by this paper
• PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease.

  2008cited by this paper
• Mycophenolate Mofetil-related Gastrointestinal Mucosal Injury: Variable Injury Patterns, Including Graft-versus-Host Disease-like Changes

  2008cited by this paper
• Chronic graft-versus-host disease.

  2008cited by this paper
• Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children

  2008cited by this paper
• Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation

  2007cited by this paper
• Infliximab for GVHD therapy in children

  2007cited by this paper
• Treatment of refractory chronic GVHD with rituximab: a GITMO study

  2007cited by this paper
• Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.

  2007cited by this paper
• Extracorporeal Photochemotherapy for the Treatment of Chronic Graft‐Versus‐Host Disease: Trend for a Possible Cell Dose‐Related Effect?

  2007cited by this paper
• Graft-versus-host disease

  2007cited by this paper
• Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.

  2007cited by this paper
• Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.

  2007cited by this paper
• Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity

  2007cited by this paper
• Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

  2007cited by this paper
• Use of infliximab‐daclizumab combination for the treatment of acute and chronic graft‐versus‐host disease of the liver and gut

  2007cited by this paper
• How I treat refractory acute GVHD.

  2007cited by this paper
• Mycophenolate Mofetil Is Effective and Well Tolerated in the Treatment of Refractory Acute and Chronic Graft-versus-Host Disease

  2006cited by this paper
• Rituximab for steroid-refractory chronic graft-versus-host disease.

  2006cited by this paper
• The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.

  2006cited by this paper
• Daclizumab for children with corticosteroid refractory graft-versus-host disease

  2006cited by this paper
• Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.

  2006cited by this paper
• Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.

  2006cited by this paper
• Thalidomide metabolism and hydrolysis: mechanisms and implications.

  2006cited by this paper
• Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

  2006cited by this paper
• Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

  2006cited by this paper
• Assessing the potential role of photopheresis in hematopoietic stem cell transplant

  2006cited by this paper
• Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

  2006cited by this paper
• Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.

  2006cited by this paper
• Chronic graft versus host disease

  2006cited by this paper
• Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.

  2006cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.

  2006cited by this paper
• Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease

  2005cited by this paper
• Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

  2005cited by this paper
• Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‐versus‐host disease

  2005cited by this paper
• Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H.

  2005cited by this paper
• Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.

  2005cited by this paper
• Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors

  2005cited by this paper
• Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation

  2005cited by this paper
• Low-dose Thoracoabdominal Irradiation for the Treatment of Refractory Chronic Graft-versus-Host Disease

  2005cited by this paper
• Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

  2005cited by this paper
• Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

  2005cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005cited by this paper
• Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

  2005cited by this paper
• Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease

  2005cited by this paper
• Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

  2004cited by this paper
• Regulation of PDGF and its receptors in fibrotic diseases.

  2004cited by this paper
• Successful use of Campath-1H in the treatment of steroid refractory liver GvHD

  2004cited by this paper
• Extracorporeal photochemotherapy for paediatric patients with graft‐versus‐host disease after haematopoietic stem cell transplantation

  2003cited by this paper
• Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

  2003cited by this paper
• Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.

  2003cited by this paper
• Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results

  2003cited by this paper
• Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response.

  2003cited by this paper
• Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

  2002cited by this paper
• Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

  2002cited by this paper
• Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

  2002cited by this paper
• Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease.

  2002cited by this paper
• Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease

  2002cited by this paper
• Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.

  2001cited by this paper
• Development of a prognostic model for grading chronic graft-versus-host disease.

  2001cited by this paper
• Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab

  2001cited by this paper
• Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.

  2001cited by this paper

• Apheresis procedures for the treatment of patients and for the collection of cellular therapy products: A British Society for Haematology guideline

  2025cites this paper
• Effect of ruxolitinib on the oral mucosa in steroid-refractory graft-versus-host disease: a prospective observational exploratory study

  2025cites this paper
• Extracorporeal Photopheresis for the Inpatient Dermatologist

  2025cites this paper
• A Vignette Study to Derive Health-Related Quality-of-Life Weights for Individuals with Steroid Refractory Chronic Graft-versus-Host Disease Receiving Third-Line Therapy in the United Kingdom

  2025cites this paper
• Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.

  2025cites this paper
• Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development

  2024cites this paper
• Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era

  2024cites this paper
• Second line extracorporeal photopheresis for cortico-resistant acute and chronic GVHD after allogeneic hematopoietic cell transplantation for hematological malignancies: Long-term results from a real-life study.

  2024cites this paper
• Oral GVHD post-cardiac xenograft valve replacement: a case report

  2024cites this paper
• Healthcare resource utilization and associated costs in patients with chronic graft-versus-host disease post allogeneic hematopoietic stem cell transplantation in England: HCRU and associated costs in patients with cGvHD in England.

  2024cites this paper
• 慢性移植物抗宿主病诊断与治疗中国专家共识（2024年版）

  2024cites this paper
• Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil

  2023cites this paper
• Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

  2023cites this paper
• Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study

  2023cites this paper
• A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease.

  2023cites this paper
• Novel therapies for graft versus host disease with a focus on cell therapies

  2023cites this paper
• Glucocorticoids, Their Uses, Sexual Dimorphisms, and Diseases: New Concepts, Mechanisms, and Discoveries.

  2023cites this paper
• Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease

  2023cites this paper
• Real-world clinical characterization, healthcare resource utilization and productivity loss in chronic graft versus host patients exposed to extracorporeal photopheresis in Sweden.

  2023cites this paper
• Extracorporeal photopheresis in the treatment of chronic graft-versus-host-disease

  2022cites this paper
• Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

  2022cites this paper
• ROCK2 Inhibition: A Futuristic Approach for the Management of Alzheimer's Disease.

  2022cites this paper
• Characterization of Hepatic Dysfunction in subjects diagnosed with Chronic GVHD by NIH Consensus Criteria.

  2022cites this paper
• High response rate and corticosteroid sparing with arsenic trioxide-based first-line therapy in cGvHD after allo-HSCT.

  2022cites this paper
• Successful desensitization of high level donor-specific anti-HLA antibody in patients with hematological diseases receiving haploidentical allografts

  2022cites this paper
• Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.

  2022cites this paper
• Abnormal liver tests are not sufficient for diagnosis of hepatic graft‐versus‐host disease in critically ill patients

  2022cites this paper
• Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease

  2022cites this paper
• Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer

  2022cites this paper
• Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement

  2022cites this paper
• Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation

  2022cites this paper
• Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

  2022cites this paper
• Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease

  2021cites this paper
• Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease

  2021cites this paper
• 体外フォトフェレーシス（extracorporeal photopheresis）による慢性移植片対宿主病の治療エビデンス

  2021cites this paper
• Open-label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in pediatric patients with Steroid-Refractory Sclerotic/fibrotic Type Chronic Graft-versus-host disease.

  2021cites this paper
• Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD

  2021cites this paper
• Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

  2021cites this paper
• Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen.

  2021cites this paper
• Steroid-refractory chronic graft-versus-host disease: treatment options and patient management

  2021cites this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.

  2021cites this paper
• An Open-label, Single-arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.

  2021cites this paper
• 慢性移植物抗宿主病（cGVHD）诊断与治疗中国专家共识（2021年版）

  2021cites this paper
• ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

  2021cites this paper
• Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD

  2021cites this paper
• Treatment of steroid‐refractory chronic graft‐versus‐host disease with imatinib: Real‐life experience of the Spanish group of hematopoietic transplantation (GETH)

  2021cites this paper
• “Is this the GVHD?” A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service

  2021cites this paper
• Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease

  2021cites this paper
• Extracorporeal Photopheresis in Graft-versus-Host Disease

  2020cites this paper
• CD71 surface analysis of T cells: a simple alternative for extracorporeal photopheresis quality control

  2020cites this paper
• Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman–Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)

  2020cites this paper
• 单倍型造血干细胞移植后糖皮质激素耐药急性移植物抗宿主病的危险因素分析

  2020cites this paper
• Ruxolitinib for the treatment of graft-versus-host disease

  2020cites this paper
• Ruxolitinib salvage therapy is effective for steroid‐refractory graft‐versus‐host disease in children: A single‐center experience

  2020cites this paper
• Cutaneous manifestations of acute and chronic graft-versus-host disease.

  2020cites this paper
• CMAR_A_283855 12287..12300

  2020cites this paper
• Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review

  2020cites this paper
• A Review on Therapeutic Management for Oral Chronic Graft-versus-Host Disease

  2020cites this paper
• Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes

  2020cites this paper
• Follicular Graft Vs Host Reaction: A Rare Presentation

  2020cites this paper
• Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT

  2020cites this paper
• Ablative Fractional Laser Resurfacing for Treatment of Sclerosis and Contractures in Chronic Graft-Versus-Host Disease: A Pilot Study.

  2020cites this paper
• Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide

  2020cites this paper
• New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

  2020cites this paper
• UK national audit of extracorporeal photopheresis (ECP) in chronic graft versus host disease

  2020cites this paper
• From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation

  2020cites this paper
• Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD)

  2020cites this paper
• Insights Into the Role of Vitamin D as a Biomarker in Stem Cell Transplantation

  2020cites this paper
• Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects

  2019cites this paper
• Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.

  2019cites this paper
• Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Graft-Versus-Host Disease

  2019cites this paper
• Systemic Diseases with an Increased Risk of Oral Squamous Cell Carcinoma

  2019cites this paper
• Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status

  2019cites this paper
• A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease

  2019cites this paper
• Feasibility of extracorporeal photopheresis in pediatric patients with graft‐versus‐host disease after hematopoietic stem cell transplantation

  2019cites this paper
• Lymphocyte counts may predict a good response to mesenchymal stromal cells therapy in graft versus host disease patients

  2019cites this paper
• Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

  2019cites this paper
• Review of Graft-Versus-Host Disease.

  2019cites this paper
• 化疗联合供者淋巴细胞输注对异基因造血干细胞移植后微小残留病阳性患者慢性移植物抗宿主病及预后的影响

  2019cites this paper
• Noninvasive imaging diagnosis of sinusoidal obstruction syndrome: a pictorial review

  2019cites this paper
• Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 109/L

  2019cites this paper
• Extracorporeal Photopheresis as a Treatment of Graft-versus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma

  2019cites this paper
• A case review of a patient experience of photopheresis using a peripherally inserted central catheter

  2018cites this paper
• Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.

  2018cites this paper
• Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease

  2018cites this paper
• Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

  2018cites this paper
• Simultaneous Extractions, Implant Placement, and Immediate Loading With Hybrid Prosthesis in Patient With Chronic Graft‐Versus‐Host Disease

  2018cites this paper
• Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation.

  2018cites this paper
• ‘Real-life’ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

  2018cites this paper
• Kutane Graft-versus-Host-Erkrankung

  2018cites this paper
• Role of Nursing in HSCT

  2018cites this paper
• Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥50 kg)

  2018cites this paper
• Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.

  2018cites this paper
• ‘To treat or not to treat’: raising awareness on the effects of graft versus host disease drugs on musculoskeletal system

  2018cites this paper
• Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation: A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology‐oncology

  2018cites this paper
• Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.

  2018cites this paper
• Extracorporeal Photopheresis Policy Number : 8 . 01 . 36 Last Review : 9 / 2018 Origination : 2 / 2002 Next Review : 9 / 2019 Policy

  2018cites this paper
• Vitamin D: is it important in haematopoietic stem cell transplantation? A review

  2018cites this paper